• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov14
Immutep Ltd. Announces Positive Phase II Trial Results for Eftilagimod Alfa in Soft Tissue Sarcoma
11:07
Oct29
Immutep Ltd. Shows Progress in LAG-3 Immunotherapy
06:49
Sep26
Analyst Storey Covers Healthcare Sector With Focus On Immutep Ltd
05:06
Aug29
Immutep released FY2025 Q4 earnings on August 28 (EST), actual revenue USD 618.59 K, actual EPS USD -0.0873
03:00
Immutep released FY2025 Q3 earnings on August 28 (EST), actual revenue USD 596.03K, actual EPS USD -0.0841
03:00
Immutep released FY2025 Annual Earnings on August 28 (EST), actual revenue USD 3.27 M (forecast USD 3.016 M), actual EPS USD -0.2735 (forecast USD -0.2392)
03:00

Schedules & Filings

Schedules
Filings
Aug28
Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 618.59 K, Net Income -12.74 M, EPS -0.0873

Feb26
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 979.06 K, Net Income -6.96 M, EPS -0.0479

Aug29
Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 577.35 K, Net Income -7.167 M, EPS -0.059

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
EKSO
10.580
+93.77%
+5.120
AEHL
2.180
+92.92%
+1.050
AFJK
82.580
+89.19%
+38.930
PFSA
0.1218
+78.33%
+0.053
DLXY
1.410
+67.86%
+0.570
ULY
2.760
+52.49%
+0.950
MENS
4.220
+51.80%
+1.440
CETX
2.980
+41.23%
+0.870
DAIC
0.5500
+39.06%
+0.154
ONTF
8.060
+37.54%
+2.200
View More